Czuczman, M S <br/><br/>
Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness.  [electronic resource] 

 -  Annals of oncology : official journal of the European Society for Medical Oncology  11 2018 
 - 2271 p.  digital 
<br/><br/> Publication Type: Journal Article; Published Erratum 
<br/><br/><label>ISSN: </label>1569-8041 
<br/><br/><label>Standard No.: </label>10.1093/annonc/mdx812  doi